TLX: TLX101-Tx and Pixclara advance neuro-oncology care with promising efficacy and regulatory momentum

The neuro-oncology pipeline features TLX101-Tx in phase III trials and Pixclara imaging under FDA review, targeting significant unmet needs in glioblastoma. Early clinical data show strong safety and promising efficacy, with a theranostic approach enabling precise patient selection and monitoring. Expansion into earlier treatment lines and additional indications is planned.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.